In winter, various respiratory infectious diseases such as influenza (flu), pneumonia, and COVID-19 are prevalent at the same ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services ...

WHO noted that prequalified tests can now be prioritized in pooled procurement mechanisms, which help lower prices, stabilize ...

Roche’s cobas BV/CV assay gains CE Mark, enabling accurate, rapid diagnosis of bacterial vaginosis and candida vaginitis.

A further easing of animal movement restrictions has been announced for farms within the Bluetongue Virus (BTV) Temporary ...

A significant number of Tuberculosis (TB) cases go undetected due to the limited sensitivity of smear microscopy, the most common diagnostic test for TB in India.

A significant number of Tuberculosis (TB) cases continue to go undetected due to the limited sensitivity of smear microscopy, the most commonly used diagnostic test for TB in India.

WHO prequalifies the first two rapid antigen detection tests for Covid-19: Geneva Saturday, December 27, 2025, 11:00 Hrs [IST] The World Health Organization (WHO) announced the pr ...

WHO has prequalified two rapid COVID-19 antigen tests, confirming their safety and quality and expanding access to fast, ...

WHO said the decision builds on earlier emergency approvals and reflects the continued need for affordable, fast COVID-19 testing even after the pandemic’s emergency phase.

Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.

Roche’s cobas liat Bordetella test earns FDA clearance, delivering accurate whooping cough results in 15 minutes.